May-12-14 Antibe Therapeutics Announces Addition to its Board of Directors and Grant of Options
May-05-14 CEO Letter to Shareholders
Apr-28-14 Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $4,259,958
Apr-07-14 Antibe Therapeutics Completes Second Closing of Non-Brokered Private Placement Bringing Total Proceeds to $3,925,358
Apr-01-14 Antibe Therapeutics Announces Discontinuation of Latin American Letter of Intent
Mar-31-14 Antibe Therapeutics Raises $3,015,398 in First Closing of Non-Brokered Private Placement
Mar-28-14 Antibe Therapeutics Announces Increase to Previously Announced Financing
Mar-21-14 Antibe Therapeutics Announces Non-Brokered Private Placement of $3,000,000
Mar-17-14 Antibe Therapeutics Announces Completion of Pre-Clinical Program for ATB-346
Mar-04-14 Antibe Therapeutics Announces Annual Compensation Changes and Grant of Stock Options
Jan-28-14 Antibe Therapeutics Announces the Final Closing of its Non-Brokered Private Placement Bringing the Total Raise Under the Offering to $1.25 Million
Jan-24-14 Antibe Therapeutics Announces Increase to Non-Brokered Private Placement
Dec-30-13 Antibe Therapeutics Raises $899,445 in Non-Brokered Private Placement
Dec-12-13 Antibe Therapeutics Announces Non-brokered Private Placement of up to $1,000,000
Nov-07-13 Dr. John Wallace, Antibe Therapeutics Founder and Chief Science Officer, awarded the Heymans Foundation Memorial Medal
Oct-22-13 Antibe Therapeutics Announces Grant of Stock Options and an Addition to its Management Team
Oct-04-13 Antibe Therapeutics Reports on Results of AGM Voting
Aug-30-13 Antibe Therapeutics Appoints New Chairman
Aug-22-13 Antibe Therapeutics Completes Final Tranche of IPO, bringing Total Raise to the Maximum Offering of $3,000,000